Stay updated with breaking news from Titles Released. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/PRNewswire/ -- RemeGen Co., Ltd. ("RemeGen" or "the Company") (9995.HK, SHA: 688331), a commercial-stage biotechnology company, announced the latest clinical...
YANTAI, China, June 5, 2023 /PRNewswire/ -- RemeGen Co., Ltd. ("RemeGen" or "the Company") (9995.HK, SHA: 688331), a commercial-stage biotechnology company, announced the latest clinical research results on disitamab vedotin (RC48) at this year's American Society of Clinical Oncology (ASCO) Annual Meeting, taking place June 2-6, 2023, in Chicago. Researchers tested disitamab vedotin and toripalimab in combination on...